AviaraDx: New Molecular Oncology Test for Metastatic & Breast Cancer
April 15, 2008 by Gloria Gamat
Filed under Diseases & Conditions
This came to my attention a while back, but for some reason got buried in my inbox. So sorry Laura!
Two new oncology tests — classifying metastatic cancer and identifying patients with estrogen receptor positive (ER+) breast cancer who are at high risk of recurrence as well as unlikely to respond favorably to standard adjuvant endocrine therapy — from AviaraDx, Inc. are now state-approved in New York.
The tests, based on proprietary AviaraDx molecular technologies, are New York state-approved and available through the company’s CAP-certified CLIA laboratory. Both can utilize small formalin-fixed and paraffin-embedded (FFPE) tissue samples easily available from imaging-guided needle biopsies.
CancerTYPE ID™ and H/I™ (HOXB13/IL17BR) are the two said tests from AviaraDx, Inc.
Read here to find out more.
[Thanks to Laura Baumgartner for the hat tip!]
